All In Biotech

Drug Trial Radar · NCT01018134

Desoximetasone Spray 0.05%, 0.25%; Dose Ranging Study

A Double-Blind, Vehicle-Controlled, Randomized, Dose Ranging, Multiple-Site Clinical Study to Evaluate the Efficacy and Safety of Desoximetasone Topical Sprays (0.05%, 0.25%) in Patients With Moderate to Severe Plaque Psoriasis

Last checked: Nov 20, 2026Latest source record: Aug 5, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 151 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

151

Actual

Start

Nov 2009

Primary completion

May 2010

Study completion May 2010

Sponsor

Sponsor type
Industry
First posted
Nov 23, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objectives of this study are to evaluate the efficacy and safety of two dosing regimens of desoximetasone 0.05% and 0.25% topical sprays as compared to a vehicle spray in patients with moderate to severe plaque psoriasis.

Conditions

  • Psoriasis

Interventions

  • Desoximetasone 0.05% once dailyDrug

    Desoximetasone topical spray 0.05% administered to affected area once daily for 28 days

  • Desoximetasone 0.05% twice dailyDrug

    Desoximetasone topical spray 0.05% administered to affected area twice daily for 28 days

  • Desoximetasone 0.25% once dailyDrug

    Desoximetasone topical spray 0.25% administered to affected area once daily for 28 days

  • Desoximetasone 0.25% once dailyDrug

    Desoximetasone topical spray 0.25% administered to affected areas twice daily for 28 days

  • Vehicle once dailyDrug

    Vehicle topical spray administered to affected areas once daily for 28 days

  • Vehicle twice dailyDrug

    Vehicle topical spray administered to affected areas twice daily for 28 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants in Each Treatment Group With Clinical Cure: Physician's Global Assessment (PGA) Score = 0 or 1 at Day 28Time frame: 28 days
  2. Number of Participants in Each Treatment Group With Treatment Success for the Target Lesion (Total Lesion Severity Scale (TLSS) a Score of 0 or 1).Time frame: Day 28

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Investigator Site

    Miami, Florida

  • Investigator Site

    Martinez, Georgia

  • Investigator Site

    Olathe, Kansas

  • Investigator Site

    Wichita, Kansas

  • Investigator Site

    Albuquerque, New Mexico

  • Investigator Site

    Cincinnati, Ohio

  • Investigator Site

    Simpsonville, South Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.